Claim136d4456010b339cd08f6b50103611b532e605e1d62dad2e33b6bce2d812e077·My Arguments

Claim

FDA analysis of 24 RCTs involving 4,582 children and adolescents found that the rate of suicidal thinking and behavior was 4% for those given an SSRI versus 2% for placebo, meaning approximately 1-3 additional patients per 100 treated developed treatment-emergent suicidality beyond baseline risk.

Evidence (1)

Intense Suicidal Thoughts and Self-Harm Following Escitalopram Treatment

Reports FDA findings of 4% vs 2% suicidality rate in SSRI vs placebo groups across 24 pediatric trials.

https://pmc.ncbi.nlm.nih.gov/articles/PMC3195160/

Embed this claim

<iframe
  src="https://www.isonomia.app/embed/claim/136d4456010b339cd08f6b50103611b532e605e1d62dad2e33b6bce2d812e077"
  width="600"
  height="280"
  frameborder="0"
  style="border: 1px solid #e5e7eb; border-radius: 8px;"
  title="Isonomia Claim"
  loading="lazy"
></iframe>

Copy and paste into any website or forum that supports HTML.

Respond to this claim on Isonomia

Build or challenge arguments with structured reasoning in the Digital Agora.

View full deliberation Join & respond